Adrenal Insufficiency Market to Grow with a CAGR of 8.86% through 2028
Rising continuous development of innovative
pharmaceutical solutions are expected to drive the Global Adrenal Insufficiency
Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Adrenal
Insufficiency Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Adrenal Insufficiency Market
stood at USD 356.21 million in 2022 and is anticipated to grow with a CAGR of 8.86%
in the forecast period, 2024-2028. Adrenal insufficiency, a rare but chronic
medical condition, has been gaining increasing attention in the global
healthcare landscape. This condition occurs when the adrenal glands do not
produce enough cortisol, a vital hormone responsible for various physiological
functions. One of the primary drivers behind the growth of the Global Adrenal
Insufficiency Market is the rising prevalence of the condition. Adrenal
insufficiency can be caused by various factors, including autoimmune diseases,
infections, and the prolonged use of medications that suppress cortisol
production. As these contributing factors become more prevalent, the number of
individuals affected by adrenal insufficiency is steadily increasing. This
trend has prompted heightened awareness and diagnosis, leading to a larger
patient population seeking treatment and management options.
Technological advancements in medical diagnostics have
played a significant role in driving the Global Adrenal Insufficiency Market.
In the past, diagnosing adrenal insufficiency could be challenging, as symptoms
often overlap with other conditions. However, modern diagnostic tools and
techniques have greatly improved the accuracy and efficiency of diagnosis. Genetic
testing, for example, can identify underlying genetic mutations associated with
adrenal insufficiency, allowing for early detection and more precise treatment
planning. Additionally, advanced imaging modalities, such as MRI and CT scans,
provide detailed information about the adrenal glands, aiding in diagnosis and
treatment decisions.
Pharmaceutical companies have been actively engaged in
developing innovative solutions for adrenal insufficiency. Traditional
treatment options typically involve the use of corticosteroid replacement
therapy to replace the missing cortisol hormone. While effective, long-term
corticosteroid use can lead to side effects and complications. As a result, the
market is witnessing the emergence of novel corticosteroid replacement therapies
that aim to provide patients with more targeted and convenient treatment
options. One such innovation is the development of sustained-release
corticosteroid formulations. These formulations release cortisol gradually,
mimicking the body's natural cortisol production pattern and reducing the risk
of side effects associated with abrupt fluctuations in hormone levels.
Additionally, researchers are exploring the use of gene therapy and
regenerative medicine approaches to restore adrenal gland function, potentially
offering a more permanent solution for some patients.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Adrenal Insufficiency Market.”
The Global Adrenal Insufficiency Market encompasses
more than just pharmaceuticals and diagnostics; it also includes the provision
of education and support services for patients and healthcare professionals.
Patient advocacy groups and healthcare organizations are collaborating to raise
awareness about adrenal insufficiency, share best practices in diagnosis and
treatment, and promote research efforts. This patient-centered approach aims to
empower individuals living with adrenal insufficiency, improve their quality of
life, and enhance their ability to manage their condition effectively.
The Global Adrenal Insufficiency Market is segmented
into Type, Treatment, Route of Administration, Distribution Channel, Regional
Distribution, And Company.
Based on the Type, the primary adrenal insufficiency
emerged as the dominant segment in the global market for Global Adrenal
Insufficiency Market in 2022. Primary adrenal insufficiency occurs when the adrenal
glands themselves are damaged or malfunctioning, leading to a deficiency in the
production of cortisol and, in some cases, aldosterone. This condition is
typically caused by autoimmune diseases, infections, or less commonly, by
genetic mutations affecting the adrenal glands. Primary adrenal insufficiency
represents the majority of adrenal insufficiency cases, making it the most
prevalent type of condition. It creates a significant demand for diagnostic
tools, treatment options, and ongoing management within the Global Adrenal
Insufficiency Market. Individuals with primary adrenal insufficiency often
require lifelong corticosteroid replacement therapy to manage their symptoms
and maintain adequate cortisol levels. This chronic treatment approach, along
with the need for continuous monitoring and care, contributes to the sustained
demand for pharmaceuticals, healthcare services, and patient support
initiatives in the market.
Based on the Treatment, the glucocorticoid segment
emerged as the dominant player in the global market for Global Adrenal
Insufficiency Market in 2022. Glucocorticoids, such as hydrocortisone
(cortisol) and prednisone, are the primary mode of treatment for adrenal
insufficiency, regardless of whether it is primary or secondary. These
medications effectively replace the deficient cortisol hormone, helping manage
the wide array of symptoms associated with adrenal insufficiency, including
fatigue, weakness, and hypotension. Furthermore, glucocorticoids are considered the
standard of care due to their affordability, availability, and well-established
safety profiles when administered under proper medical supervision. Patients
with adrenal insufficiency typically require daily glucocorticoid therapy to
maintain cortisol levels within the normal range, making it a consistently
high-demand treatment.
Based on the Distribution Channel, the Retail
Pharmacies segment emerged as the dominant player in the global market for
Global Adrenal Insufficiency Market in 2022. Retail pharmacies are easily
accessible to the general population, offering a convenient location for
patients to obtain their prescribed medications. Individuals with adrenal
insufficiency often require regular access to corticosteroid replacement
therapy, making the proximity of retail pharmacies invaluable. Retail
pharmacists are trained healthcare professionals who can provide guidance and
answer questions about medication regimens and potential drug interactions.
Given the complexities of adrenal insufficiency management, having access to
knowledgeable pharmacists is crucial for patients.
Retail pharmacies can dispense medications promptly,
ensuring that patients have timely access to essential corticosteroids,
allowing for consistent cortisol replacement and symptom management.
North America emerged as the dominant player in the
global Adrenal Insufficiency Market in
2022, holding the largest market share. The region has a high prevalence of
diabetes, which naturally leads to a larger population at risk of developing
diabetic gastroparesis. Secondly, North America is home to advanced healthcare
infrastructure, including well-established pharmaceutical and medical device
industries, facilitating research, development, and access to innovative
treatments.
Also, Autoimmune diseases, a leading cause of primary
adrenal insufficiency, are relatively prevalent in North America. Conditions
such as autoimmune thyroiditis and type 1 diabetes often co-occur with adrenal
insufficiency. This higher prevalence of underlying autoimmune disorders
contributes to a larger patient population with adrenal insufficiency.
Major companies operating in Global Adrenal
Insufficiency Market are:
- Acrotech Biopharma,
Inc.
- Bausch Health,
Canada Inc
- AdvaCare Pharma
- Weefselpharma
- Cipla Inc.
- Pfizer Inc
- Wellona Pharma
- Eugia US
- Sandoz Inc.
- Prevego Healthcare
& Research Pvt Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Adrenal Insufficiency Market is poised for substantial growth in the coming
years, driven by several key factors. Firstly, the increasing prevalence of
autoimmune diseases, infections, and the prolonged use of medications that can
lead to adrenal insufficiency is expanding the patient pool, thereby boosting
market demand. Additionally, rising awareness among both healthcare professionals
and the general public is facilitating early diagnosis and treatment
initiation. Furthermore, ongoing advancements in diagnostic tools and
techniques, including genetic testing, are enhancing diagnostic precision,
leading to more accurate identification of adrenal insufficiency cases.
Innovations in pharmaceutical solutions, such as sustained-release
corticosteroid formulations and gene therapy research, promise to improve
treatment efficacy and minimize side effects, contributing to market growth.The
adoption of telemedicine and remote monitoring technologies is improving
patient access to care, while combination therapies and personalized medicine
approaches are providing more comprehensive and tailored treatment options..” said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Adrenal Insufficiency Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By
Type (Primary, Secondary, Tertiary), By Treatment (Glucocorticoid,
Corticotropin, Others), By Route of Administration (Oral, Injectables, Others),
By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies) By Region and Competition”, has evaluated the future growth potential of Global
Adrenal Insufficiency Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Adrenal
Insufficiency Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan, NY,
New York –
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com